3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Expanded_access
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
8
Leukemia, Lymphocytic, Chronic, B-Cell
6
Melanoma
5
Lymphoma, T-Cell, Cutaneous
5
Carcinoma, Ovarian Epithelial
5
Sezary Syndrome
4
Mycosis Fungoides
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Follicular
4
Lymphoma, Large B-Cell, Diffuse
3
Leukemia
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Waldenstrom Macroglobulinemia
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Neoplasms by Histologic Type
1
Interventions
Cyclophosphamide
151
Dexamethasone
140
Rituximab
83
fludarabine
78
Cytarabine
69
Lenalidomide
68
Bortezomib
63
fludarabine phosphate
62
Gemcitabine
62
venetoclax
54
Etoposide
53
pembrolizumab
52
pomalidomide
48
Paclitaxel
48
Cisplatin
47
Carboplatin
47
Peripheral Blood Stem Cell Transplantation
46
Filgrastim
40
Radiotherapy
39
Calcium Dobesilate
36
Busulfan
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
29
Vincristine
28
Temozolomide
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Recurrence
×
denileukin diftitox
×
Clear all
NCT00801918
2013-05-15
Denileukine Diftitox for Relapsed ALCL
Columbia University
Phase 2
Withdrawn